Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Microbial Identification Using MALDI-TOF MS. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Microbial Identification Using MALDI-TOF MS (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 111 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Verification and Validation of MALDI-TOF MS Performance

Clinical Laboratories must verify (initial startup) or validate (ongoing process) instrumentation and associated databases when implementing and routinely using MALDI-TOF MS for clinical diagnostics. The purpose of verification and validation studies is to assess the instrument’s performance in each laboratory. The benefit to using an FDA-cleared instrument is that these devices have gone through rigorous clinical trials and have been extensively evaluated. As a result, the testing required to verify the instrument’s performance is minimal and well-defined. Specific guidance for the verification of the FDA-cleared MALDI-TOF MS instruments is recommended in a recent Clinical and Laboratory Standards Institute (CLSI) document (M58) titled, Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry, 1st Edition. The key parameters include accuracy, where MALDI-TOF MS results are compared to identification by reference methods and precision, where results with well-characterized strains show reproducibility of results within runs, between runs, day-to-day, and between technologists.
Organisms not included in the FDA clinically approved (CA) list must be subjected to evaluation as a laboratory developed tests (LDTs). The validation requirements for LDTs are less clear and not well defined for MALDI-TOF MS. The design for these types of validation studies is at the discretion of the laboratory director. In a survey of several major academic medical center laboratories using LDT MALDI-TOF MS, there was some consensus with respect to validation studies performed by each individual laboratory (Doern et al. 2013). Laboratories generally validated their LDT MALDI-TOF MS systems by testing around 1,000 total isolates and comparing the MALDI identifications to conventional laboratory methods and resolving discrepancies with 16s rRNA sequencing. Laboratories performed their analyses by microorganism category. For example, gram-negative, gram-positive, and yeasts were all analyzed separately. CLSI's M-58 standard details a consensus procedure.